KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $444.2 million.

  • Royalty Pharma's Net Income towards Common Stockholders fell 4491.14% to $444.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 2400.27%. This contributed to the annual value of $1.3 billion for FY2024, which is 2172.09% down from last year.
  • As of Q3 2025, Royalty Pharma's Net Income towards Common Stockholders stood at $444.2 million, which was down 4491.14% from $90.6 million recorded in Q2 2025.
  • Royalty Pharma's Net Income towards Common Stockholders' 5-year high stood at $806.8 million during Q2 2021, with a 5-year trough of -$610.0 million in Q4 2022.
  • For the 5-year period, Royalty Pharma's Net Income towards Common Stockholders averaged around $287.9 million, with its median value being $221.8 million (2021).
  • As far as peak fluctuations go, Royalty Pharma's Net Income towards Common Stockholders plummeted by 123661.01% in 2022, and later surged by 1024352.91% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Net Income towards Common Stockholders stood at $53.7 million in 2021, then crashed by 1236.61% to -$610.0 million in 2022, then soared by 217.63% to $717.6 million in 2023, then tumbled by 53.41% to $334.4 million in 2024, then soared by 32.86% to $444.2 million in 2025.
  • Its Net Income towards Common Stockholders was $444.2 million in Q3 2025, compared to $90.6 million in Q2 2025 and $433.4 million in Q1 2025.